Bronchopulmonary Dysplasia: a Modern View on Course and Outcomes
https://doi.org/10.15690/pf.v13i4.1609
Abstract
The studying of various courses and outcomes of bronchopulmonary dysplasia is an important direction of modern pediatric research. Researchers of different profiles have an interest in the issue not only due to the recent publication of results obtained after 50-yearlong observations which occurred since the disease has been described for the first time, but also due to the successes of functional diagnostics and the improvements made in visualizing structural lesions in the lungs. The review describes the modern concepts concerning the course of bronchopulmonary dysplasia, as well as the factors affecting the disease outcomes.
References
1. Баранов А.А., Намазова-Баранова Л.С., Давыдова И.В. Современные подходы к профилактике, диагностике и лечению бронхолегочной дисплазии. — М.: ПедиатрЪ; 2013. 176 с. [Baranov AA, Namazova-Baranova LS, Davydova IV. Sovremennye podkhody k profilaktike, diagnostike i lecheniyu bronkholegochnoi displazii. Moscow: Pediatr»»; 2013. 176 p. (In Russ).]
2. Российское респираторное общество. Классификация клинических форм бронхолегочных заболеваний у детей // Педиатрия. Журнал им. Г.Н. Сперанского. — 2010. — Т. 89. — № 4. — С. 6–15. [Rossiiskoe respiratornoe obshchestvo. Klassifikatsiya klinicheskikh form bronkholegochnykh zabolevanii u detei. Pediatriia. 2010;89(4):6–15. (In Russ).]
3. Союз педиатров России. Федеральные клинические рекомендации по ведению детей с бронхолегочной дисплазией. — М.; 2014. 28 с. [Soyuz pediatrov Rossii. Federal’nye klinicheskie rekomendatsii po vedeniyu detei s bronkholegochnoi displaziei. Moscow; 2014. 28 p. (In Russ).]
4. Овсянников Д.Ю., Кузьменко Л.Г., Дегтярева Е.А. Брон холегочная дисплазия у детей / Болезни органов дыхания. [Ovsyannikov DYu, Kuz’menko LG, Degtyareva EA. Bronkholegochnaya displaziya u detei. In: Bolezni organov dykhaniya. (In Russ).] Доступно по: http://www.medvuz.com/med1808/t5/2.php. Ссылка активна на 13.06.2016.
5. Бойцова Е.В., Богданова А.В., Овсянников Д.Ю. Последствия бронхолегочной дисплазии для респираторного здоровья детей, подростков и молодых взрослых // Вопросы диагностики в педиатрии. — 2013. — Т. 5. — № 1. — С. 5–11. [Boytsova EV, Bogdanova AV, Ovsyannikov DYu. The consequences of bronchopulmonary dysplasia for respiratory health of children, adolescents and young adults. Voprosy diagnostiki v pediatrii. 2013;5(1):5–11. (In Russ).]
6. Патент на изобретение № 0240166. Яцык Г.В., Давыдова И.В., Кустова О.В. Способ оценки степени тяжести бронхолегочной дисплазии. Зарегистрировано в Государственном реестре изобретений РФ от 10.10.2010. [Patent RUS № 0240166/10.10.2010. Zaregistrirovano v Gosudarstvennom reestre izobretenii RF. Yatsyk GV, Davydova IV, Kustova OV. Sposob otsenki stepeni tyazhesti bronkholegochnoi displazii. (In Russ).]
7. American Academy of Pediatrics, Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics. 2002;109(2):330–338. doi: 10.1542/peds.109.2.330.
8. Давыдова И.В., Цыгина Е.Н., Кустова О.В. и др. Особенности диагностики врожденной патологии органов дыхания у детей с бронхолегочной дисплазией // Российский педиатрический журнал. — 2008. — № 3. — С. 4–6. [Davydova IV, Tsygina YeN, Kustova OV, et al. Diagnosis of congenital respiratory diseases in children with bronchopulmonary dysplasia. Rossiiskii pediatricheskii zhurnal. 2008;(3):4–6. (In Russ).]
9. Давыдова И.В., Намазова-Баранова Л.С., Яцык Г.В. и др. Профилактические стратегии на этапах формирования и течения бронхолегочной дисплазии // Педиатрическая фармакология. — 2014. — Т. 11. — № 2. — С. 34–40. [Davydova IV, Namazova-Baranova LS, Yatsyk GV, et al. Preventive strategies in the stages of formation and course of bronchopulmonary dysplasia. Pediatric pharmacology. 2014;11(2):34–40. (In Russ).] doi: 10.15690/pf.v11i2.955.
10. Давыдова И.В., Аникин А.В., Кустова О.В. и др. Бронхолегочная дисплазия в постсурфактантную эру: результаты объективной оценки течения заболевания // Вопросы современной педиатрии. — 2015. — Т. 14. — № 4. — С. 514–518. [Davydova IV, Anikin AV, Kustova OV, et al. Bronchopulmonary dysplasia in post-surfactant era: results of an objective assessment of the disease. Current pediatrics. 2015;14(4):514–518. (In Russ).] doi: 10.15690/vsp.v14.i4.1392.
11. Давыдова И.В. Формирование, течение и исходы бронхолегочной дисплазии у детей: автореф. дис. … докт. мед. наук. — М.; 2010. 48 с. [Davydova IV. Formirovanie, techenie i iskhody bronkholegochnoi displazii u detei. [dissertation abstract] Moscow; 2010. 48 p. (In Russ).]
12. Greenough A, Kotecha S, Vrijlandt E. Bronchopulmonary dysplasia: current models and concepts. In: Respiratory diseases in infants and children. European Respiratory Society; 2006. p. 217–233. doi: 10.1183/1025448x.00037014.
13. Glowacka E, Lis G. Bronchopulmonary dysplasia early and longterm pulmonary sequelae. [Polish] Pneumonol Alergol Pol. 2008; 76(6):437–445.
14. Wong PM, Lees AN, Louw J, et al. Emphysema in young adult survivors of moderate-to-severe bronchopulmonary dysplasia. Eur Respir J. 2008;32(2):321–328. doi: 10.1183/09031936.00127107.
15. Овсянников Д.Ю. Система оказания медицинской помощи детям, страдающим бронхолегочной дисплазией. Руководство для практикующих врачей. — М.: МДВ; 2010. 152 с. [Ovsyannikov DYu. Sistema okazaniya meditsinskoi pomoshchi detyam, stradayushchim bronkholegochnoi displaziei. Rukovodstvo dlya praktikuyushchikh vrachei. Moscow: MDV; 2010. 152 p. (In Russ).]
16. Rona RJ, Gulliford MC, Chinn S. Effects of prematurity and intrauterine growth on respiratory health and lung function in childhood. BMJ. 1993;306(6881):817–820. doi: 10.1136/bmj.306.6881.817.
17. Northway WH, Jr., Moss RB, Carlisle KB, et al. Late pulmonary sequelae of bronchopulmonary dysplasia. N Engl J Med. 1990; 323(26):1793–1799. doi: 10.1056/NEJM199012273232603.
18. Старевская С.В. Бронхолегочная дисплазия у детей (факторы риска формирования, клинико-рентгенологические особенности различной степени тяжести заболевания): автореф. дис. ... канд. мед. наук. — СПб.; 2001. 21 с. [Starevskaya SV. Bronkholegochnaya displaziya u detei (faktory riska formirovaniya, kliniko-rentgenologicheskie osobennosti razlichnoi stepeni tyazhesti zabolevaniya). [dissertation abstract] St. Petersburg.; 2001. 21 p. (In Russ).]
19. Vrijlandt EJLE, Duivrman EJ. Pulmonary function testing in premature infants and infants with bronchopulmonary dysplasia. In: Frey U, Merkus PJFM, editors. Pediatric lung function. V. 47. European Respiratory Society; 2010. p. 251–262. doi: 10.1183/1025448x.00011309.
20. Doyle LW, Victorian Infant Collaborative Study G. Respiratory function at age 8-9 years in extremely low birthweight/very preterm children born in Victoria in 1991–1992. Pediatr Pulmonol. 2006;41(6):570–576. doi: 10.1002/ppul.20412.
21. Doyle LW, Faber B, Callanan С, et al. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics. 2006;118(1):108–113. doi: 10.1542/peds.2005-2522.
22. Aukland SM, Halvorsen T, Fosse KR, et al. High-resolution CT of the chest in children and young adults who were born prematurely: findings in a population-based study. AJR Am J Roentgenol. 2006;187(4):1012–1018. doi: 10.2214/AJR.05.0383.
23. Овсянников Д.Ю., Кузьменко Л.Г., Дегтярева Л.А., Зайцева Э.Г. Течение бронхолегочной дисплазии у детей грудного и раннего возраста // Педиатрия. Журнал им. Г.Н. Сперанского. — 2007. — Т. 86. — № 4. — С. 35–42. [Ovsyannikov DYu, Kuz’menko LG, Degtyareva LA, Zaitseva EG. Bronchopulmonary dysplasia in infants. Pediatriia. 2007;86(4):35–42. (In Russ).]
24. Mahut B, De Blic J, Emond S, et al. Chest computed tomography findings in bronchopulmonary dysplasia and correlation with lung function. Arch Dis Child Fetal Neonatal Ed. 2007;92(6):F459–464. doi: 10.1136/adc.2006.111765.
25. Овсянников Д.Ю., Комлева Н.А., Оболадзе Т.Б. и др. Современные алгоритмы диагностики бронхолегочной дисплазии // Вопросы диагностики в педиатрии. — 2011. — Т. 3. — № 1. — С. 12–20. [Ovsyannikov DYu, Komleva NA, Oboladze TB, et al. Modern algorithms for diagnostics of bronchopulmonary dysplasia. Voprosy diagnostiki v pediatrii. 2011;3(1):12–20. (In Russ).]
26. medconfer.com [интернет]. Сергеева О.В. Стратификация риска развития бронхолегочной дисплазии у недоношенных новорожденных. Бюллетень медицинских Интернет-конференций. — 2012. — Т. 2. — № 11. — 2012-11-376-A-1774. [Sergeeva OV. Stra tifikatsiya riska razvitiya bronkholegochnoi displazii u nedonoshennykh novorozhdennykh. Bulletin of Medical Internet Conferences. 2012; 2(11):ID:2012-11-376-A-1774. (In Russ).] Доступно по: http://medconfer.com/node/1774. Ссылка активна на 19.07.2016.
27. Hayes D, Jr., Meadows JT, Jr., Murphy BS, et al. Pulmonary function outcomes in bronchopulmonary dysplasia through childhood and into adulthood: implications for primary care. Prim Care Respir J. 2011;20(2):128–133. doi: 10.4104/pcrj.2011.00002.
28. De Paepe ME, Greco D, Mao Q. Angiogenesis-related gene expression profiling in ventilated preterm human lungs. Exp Lung Res. 2010;36(7):399–410. doi: 10.3109/01902141003714031.
29. Mailaparambil B, Krueger M, Heizmann U, et al. Genetic and epidemiological risk factors in the development of bronchopulmonary dysplasia. Dis Markers. 2010;29(1):1–9. doi: 10.3233/DMA-2010-0720.
30. Володин Н.Н. Бронхолегочная дисплазия. Учебно-методическое пособие. — М.: РГМУ; 2010. 56 с. [Volodin NN. Bronkholegochnaya displaziya. Uchebno-metodicheskoe posobie. Moscow: RGMU; 2010. 56 p. (In Russ).]
31. Caputo S, Furcolo G, Rabuano R, et al. Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil. J Cardiovasc Med (Hagerstown). 2010;11(9):704–706. doi: 10.2459/JCM.0b013e328332e745.
32. Hyvarinen MK, Kotaniemi-Syrjanen A, Reijonen TM, et al. Lung function and bronchial hyper-responsiveness 11 years after hospitalization for bronchiolitis. Acta Paediatr. 2007;96(10):1464–1469. doi: 10.1111/j.1651-2227.2007.00458.x.
33. Eryigit-Madzwamuse S, Strauss V, Baumann N, et al. Personality of adults who were born very preterm. Arch Dis Child Fetal Neonatal Ed. 2015;100(6):F524–529. doi: 10.1136/archdischild-2014-308007.
34. Kajantie E, Strang-Karlsson S, Hovi P, et al. Adults born at very low birth weight exercise less than their peers born at term. J Pediatr. 2010;157(4):610–616.e611. doi: 10.1016/j.jpeds.2010.04.002.
35. Hovi P, Andersson S, Eriksson JG, et al. Glucose regulation in young adults with very low birth weight. N Engl J Med. 2007;356(20): 2053–2063. doi: 10.1056/NEJMoa067187.
36. Hovi P, Andersson S, Raikkonen K, et al. Ambulatory blood pressure in young adults with very low birth weight. J Pediatr. 2010;156(1):54–59.e51. doi: 10.1016/j.jpeds.2009.07.022.
37. Schmidt B, Roberts RS, Davis PG, et al. Prediction of late death or disability at age 5 years using a count of 3 neonatal morbidities in very low birth weight infants. J Pediatr. 2015;167(5):982–986.e982. doi: 10.1016/j.jpeds.2015.07.067.
38. Nobile S, Noviello C, Cobellis G, Carnielli VP. Infants with bronchopulmonary dysplasia prone to gastroesophageal reflux? A prospective observational study with Esophageal pH-Impedance monitoring. J Pediatr. 2015;167(2):279–285.e271. doi: 10.1016/j.jpeds.2015.05.005.
39. Wheeler K, Klingenberg C, McCallion N, et al. Volume-targeted versus pressure-limited ventilation in the neonate. Cochrane Database Syst Rev. 2010;(11):CD003666. doi: 10.1002/14651858.CD003666.pub3.
40. Finer NN, Carlo WA, et al. Early CPAP versus surfactant in extremely preterm infants. N Engl J Med. 2010;362(21):1970–1979. doi: 10.1056/NEJMoa0911783.
41. Kribs A, Hartel C, Kattner E, et al. Surfactant without intubation in preterm infants with respiratory distress: first multi-center data. Klin Padiatr. 2010;222(1):13–17. doi: 10.1055/s-0029-1241867.
42. Wu SY, Sachin G, Chung-Ming C, Tsu-Fuh Y. Bronchopulmonary dysplasia, lung diseases — selected state of the art reviews [Internet]. Ed by Dr. M.I. Elvisegran. InTech; 2012. 690 p [cited 2016 Jun 21]. Available from: http://www.intechopen.com/books/lungdiseases-selected-state-of-the-artreviews/bronchopulmonarydysplasia.
43. Баранов А.А., Альбицкий В.Ю. Смертность детского населения России (тенденции, причины и пути снижения). — М.: Союз педиатров России; 2009. С. 342–347. [Baranov AA, Al’bitskii VYu. Smertnost’ detskogo naseleniya Rossii (tendentsii, prichiny i puti snizheniya). Moscow: Soyuz pediatrov Rossii; 2009. p. 342–347. (In Russ).]
44. Давыдова И.В., Мигали А.В., Акоев Ю.С. и др. Возможность благоприятного исхода бронхолегочной дисплазии у ребенка с тяжелым течением заболевания // Справочник педиатра. — 2011. — № 4. — С. 33–39. [Davydova IV, Migali AV, Akoev YuS, et al. Vozmozhnost’ blagopriyatnogo iskhoda bronkholegochnoi displazii u rebenka s tyazhelym techeniem zabolevaniya. Spravochnik pediatra. 2011;(4):33–39. (In Russ).]
45. Российское респираторное общество. Бронхолегочная дисплазия у детей. Научно-практическая программа. — М.; 2012. 80 с. [Rossiiskoe respiratornoe obshchestvo. Bronkholegochnaya displaziya u detei. Nauchno-prakticheskaya programma. Moscow; 2012. 80 p. (In Russ).]
46. Horbar JD, Soll RF, Edwards WH. The Vermont Oxford Network: a community of practice. Clin Perinatol. 2010;37(1):29–47. doi: 10.1016/j.clp.2010.01.003.
47. Engle WA. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419–432. doi: 10.1542/peds.2007-328.
48. Антонов А.Г., Борисевич О.А., Буркова А.С. и др. Методическое письмо «Интенсивная терапия и принципы выхаживания детей с экстремально низкой и очень низкой массой тела при рождении» / Под ред. Д.Н. Дегтярева. — М.; 2011. 72 с. [Antonov AG, Borisevich OA, Burkova AS, et al. Metodicheskoe pis’mo «Intensivnaya terapiya i printsipy vykhazhivaniya detei s ekstremal’no nizkoi i ochen’ nizkoi massoi tela pri rozhdenii». Ed by D.N. Degtyarev. Moscow; 2011. 72 p. (In Russ).]
49. Рындин А.Ю., Антонов А.Г. Патент RU 2416388 C1 Способ профилактики бронхолегочной дисплазии у новорожденных с очень низкой и экстремально низкой массой тела при рождении. Опубл. в бюллетене № 11 от 20.04.2011. [Patent RU 2416388/20.04.2011. Byul. №11. Ryndin AYu, Antonov AG. C1 Sposob profilaktiki bronkholegochnoi displazii u novorozhdennykh s ochen’ nizkoi i ekstremal’no nizkoi massoi tela pri rozhdenii. (In Russ).]
50. Gyamfi-Bannerman C, Thom EA. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016; 375(5):486–487. doi: 10.1056/NEJMc1605902.
51. Wu SY, Tessy J, Medha K, et al. Postnatal corticosteroid to prevent or treat chronic lung disease in preterm infants. Neonatology Today. 2009;4(11):1–8.
52. Halliday HL, Ehrenkranz RA, Doyle LW. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2009(1):CD001145. doi: 10.1002/14651858. CD001145.pub2.
53. Yeh TF, Lin HC, Chang CH, et al. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study. Pediatrics. 2008;121(5): e1310–1318. doi: 10.1542/peds.2007-1973.
54. Kuo HT, Lin HC, Tsai CH, et al. A follow-up study of preterm infants given budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants. J Pediatr. 2010;156(4):537–541. doi: 10.1016/j.jpeds.2009.10.049.
55. Wilson TT, Waters L, Patterson CC, et al. Neurodevelopmental and respiratory follow-up results at 7 years for children from the United Kingdom and Ireland enrolled in a randomized trial of early and late postnatal corticosteroid treatment, systemic and inhaled (the Open Study of Early Corticosteroid Treatment). Pediatrics. 2006;117(6):2196–2205. doi: 10.1542/peds.2005-2194.
56. Bassler D, Plavka R, Shinwell ES, et al. Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia. N Engl J Med. 2015;373(16):1497–1506. doi: 10.1056/NEJMoa1501917.
57. Lister P, Iles R, Shaw B, Ducharme FM. WITHDRAWN. Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev. 2010(1):CD002311. doi: 10.1002/14651858.CD002311.pub2.
58. Field D, Elbourne D, Truesdale A, et al. Neonatal Ventilation With Inhaled Nitric Oxide Versus Ventilatory Support Without Inhaled Nitric Oxide for Preterm Infants With Severe Respiratory Failure: the INNOVO multicentre randomised controlled trial (ISRCTN 17821339). Pediatrics. 2005;115(4):926–936. doi: 10.1542/peds.2004-1209.
59. Mestan KK, Marks JD, Hecox K, et al. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med. 2005;353(1):23–32. doi: 10.1056/NEJMoa043514.
60. Ventre K, Haroon M, Davison C. Surfactant therapy for bronchiolitis in critically ill infants. Cochrane Database Syst Rev. 2006;(3):CD005150. doi: 10.1002/14651858.CD005150.pub2.
61. Cole FS, Alleyne C, Barks JD, et al. NIH consensus development conference: Inhaled nitric oxide therapy for premature infants. Pediatrics. 2011;127(2):363–369. doi: 10.1542/peds.2010-3507.
62. Mercier JC, Hummler H, Durrmeyer X, et al. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet. 2010;376(9738): 346–354. doi: 10.1016/S0140-6736(10)60664-2.
63. Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010; (1):CD000273. doi: 10.1002/14651858.CD000273.pub2.
64. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19): 1893–1902. doi: 10.1056/NEJMoa073679.
65. Doyle LW, Schmidt B, Anderson PJ, et al. Reduction in developmental coordination disorder with neonatal caffeine therapy. J Pediatr. 2014;165(2):356–359.e352. doi: 10.1016/j.jpeds.2014.04.016.
66. Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;(9):CD001453. doi: 10.1002/14651858. CD001453.pub2.
67. Stewart A, Brion LP, Ambrosio-Perez I. Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev. 2011;(9):CD001817. doi: 10.1002/14651858.CD001817.pub2.
68. Таточенко В.К. Вакцинация недоношенных и маловесных детей // Педиатрическая фармакология. — 2013. — Т. 10. — № 4. — С. 30–37. [Tatochenko VK. Vaccination of premature/lowbirth-weight children. Pediatric pharmacology. 2013;10(4):30–37. (In Russ).] doi: 10.15690/pf.v10i4.752.
69. Checchia PA, Nalysnyk L, Fernandes AW, et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis. Pediatr Crit Care Med. 2011;12(5):580–588. doi: 10.1097/pcc.0b013e3182070990.
70. Баранов А.А., Давыдова И.В., Турти Т.В. и др. Иммуно профилактика тяжелого течения респираторно-синцитиальной вирусной инфекции у детей с бронхолегочной дисплазией: результаты четырех эпидемических сезонов // Педиатрическая фармакология. — 2012. — Т. 9. — № 6. — С. 48–53. [Baranov AA, Davydova IV, Turti TV, et al. Immunoprophylaxis of severe respiratory-syncytial viral infection in children with bronchopulmonary dysplasia: results of 4 epidemic seasons. Pediatric pharmacology. 2012;9(6):48–53. (In Russ).] doi: 10.15690/pf.v9i6.518.
71. van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180(11):1131–1142. doi: 10.1164/rccm.200902-0179OC.
72. Balasubramaniam V, Ryan SL, Seedorf GJ, et al. Bone marrowderived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol Lung Cell Mol Physiol. 2010;298(3):L315–323. doi: 10.1152/ajplung.00089.2009.
Review
For citations:
Kazakova K.A. Bronchopulmonary Dysplasia: a Modern View on Course and Outcomes. Pediatric pharmacology. 2016;13(4):367-372. (In Russ.) https://doi.org/10.15690/pf.v13i4.1609
Views:
1378
Email this article 